• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童期苯妥英钠的消除:浓度依赖性动力学的影响。

Phenytoin elimination in childhood: effect of concentration-dependent kinetics.

作者信息

Dodson W E

出版信息

Neurology. 1980 Feb;30(2):196-9. doi: 10.1212/wnl.30.2.196.

DOI:10.1212/wnl.30.2.196
PMID:7188800
Abstract

The effect of phenytoin (PHT) concentration on the elimination rate of PHT was evaluated in infants, children, and young adults ranging in age from 1 day to 22 years. As PHT concentration increased, the effective half-life (t50%) increased. In eight children, age 7 months to 4.83 years with initial concentrations between 10 to 20 mg per liter, the average t50% (18.6 hours) was approximately 58% as long as the average in adults with comparable concentrations. Whereas the t50% correlated with the initial PHT concentrations, there was no correlation overall between t50% and age, size, or number of other antiepileptic medications taken. The concentration-dependence of the t50% provided the basis for less frequent dosing than one would expect from previous studies of PHT half-life in children with low concentrations.

摘要

在年龄从1天到22岁的婴儿、儿童和青年中评估了苯妥英(PHT)浓度对PHT消除率的影响。随着PHT浓度的增加,有效半衰期(t50%)延长。在8名年龄为7个月至4.83岁、初始浓度在每升10至20毫克之间的儿童中,平均t50%(18.6小时)约为浓度相当的成年人平均t50%的58%。虽然t50%与初始PHT浓度相关,但总体上t50%与年龄、体型或服用的其他抗癫痫药物数量之间没有相关性。t50%的浓度依赖性为比以前对低浓度儿童PHT半衰期研究预期的给药频率更低提供了依据。

相似文献

1
Phenytoin elimination in childhood: effect of concentration-dependent kinetics.儿童期苯妥英钠的消除:浓度依赖性动力学的影响。
Neurology. 1980 Feb;30(2):196-9. doi: 10.1212/wnl.30.2.196.
2
Phenytoin elimination in newborns.新生儿体内苯妥英钠的消除
Neurology. 1983 Feb;33(2):173-8. doi: 10.1212/wnl.33.2.173.
3
Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
Ther Drug Monit. 1985;7(4):405-10. doi: 10.1097/00007691-198512000-00007.
4
Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.成人及老年癫痫患者维持治疗期间苯妥英钠的半衰期及清除率
Neurology. 2008 Jul 1;71(1):38-43. doi: 10.1212/01.wnl.0000316392.55784.57.
5
Phenytoin kinetics in children.儿童苯妥英钠的药代动力学
Neurology. 1976 Aug;26(8):715-20. doi: 10.1212/wnl.26.8.715.
6
Nonlinear kinetics of phenytoin in children.苯妥英钠在儿童体内的非线性动力学
Neurology. 1982 Jan;32(1):42-8. doi: 10.1212/wnl.32.1.42.
7
Time-dependent interaction between phenytoin and valproic acid.苯妥英钠与丙戊酸之间的时间依赖性相互作用。
Neurology. 1985 Apr;35(4):510-5. doi: 10.1212/wnl.35.4.510.
8
Antiepileptic drug utilization in pediatric patients.儿科患者的抗癫痫药物使用情况。
Epilepsia. 1984;25 Suppl 2:S132-9. doi: 10.1111/j.1528-1157.1984.tb05645.x.
9
Phenytoin kinetics in children.儿童苯妥英钠的药代动力学
Clin Pharmacol Ther. 1980 May;27(5):704-7. doi: 10.1038/clpt.1980.100.
10
In vivo binding characteristics of phenytoin to serum proteins in monotherapy for adults with epilepsy.苯妥英在成人癫痫单药治疗中与血清蛋白的体内结合特性。
Am J Ther. 2000 Nov;7(6):359-63. doi: 10.1097/00045391-200007060-00004.

引用本文的文献

1
KCNQ2 related early-onset epileptic encephalopathies in Chinese children.KCNQ2 相关的早发性癫痫性脑病在我国儿童中的发病情况。
J Neurol. 2019 Sep;266(9):2224-2232. doi: 10.1007/s00415-019-09404-y. Epub 2019 May 31.
2
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.抗癫痫药物在儿科患者中的临床药代动力学。第二部分。苯妥英、卡马西平、舒噻美、拉莫三嗪、氨己烯酸、奥卡西平和非氨酯。
Clin Pharmacokinet. 1995 Nov;29(5):341-69. doi: 10.2165/00003088-199529050-00004.
3
Therapeutic drug monitoring.
Indian J Pediatr. 1986 Mar-Apr;53(2):149-62. doi: 10.1007/BF02748503.
4
Clinical features and management of poisoning due to phenytoin.苯妥英中毒的临床特征与处理
Med Toxicol Adverse Drug Exp. 1989 Jul-Aug;4(4):229-45. doi: 10.1007/BF03259910.
5
Pharmacokinetics of drugs in overdose.
Clin Pharmacokinet. 1992 Aug;23(2):93-105. doi: 10.2165/00003088-199223020-00003.